PDGFRα Antibody

Olaratumab, LY3012207, IMC-3G3
Olaratumab is being investigated in clinical trials in patients with pancreatic cancer or sarcoma.

**Clinical Development**

Olaratumab (LY3012207, IMC-3G3) is a human IgG1 monoclonal antibody that has been shown in vitro to bind to human PDGFR α.

**Molecule**

PDGFR α is expressed in multiple tumor types, and its aberrant activation has been implicated in cancer. Gene amplification and activating mutations of PDGFR α have been associated with increased metastatic potential in preclinical models. Coexpression of PDGFR α and PDGFs, consistent with autocrine-mediated growth, has been found in subsets of glioblastomas, non-small cell lung cancers, and gastrointestinal stromal tumors. PDGFR α expression has been implicated in cancer. Coexpression of PDGFR α and PDGFs, consistent with autocrine-mediated growth, has been found in subsets of glioblastomas, non-small cell lung cancers, and gastrointestinal stromal tumors.

**Target**

PDGFR α is a receptor tyrosine kinase that mediates signaling from PDGF ligands, and its activation has been implicated in cancer. Competitive inhibitors of PDGFR α, combined with radiation or chemotherapy, have been shown to be effective against various cancers in animal models.

**Targeted Therapy**

PDGFR α is a receptor tyrosine kinase that mediates signaling from PDGF ligands, and its activation has been implicated in cancer.

**Targeting**

PDGFR α is a receptor tyrosine kinase that mediates signaling from PDGF ligands, and its activation has been implicated in cancer.

**PDGFR Antibody**

Olaratumab (LY3012207, IMC-3G3) is a human IgG1 monoclonal antibody that has been shown in vitro to bind to human PDGFR α.

**Targeted Therapy**

PDGFR α is a receptor tyrosine kinase that mediates signaling from PDGF ligands, and its activation has been implicated in cancer. Gene amplification and activating mutations of PDGFR α have been associated with increased metastatic potential in preclinical models. Coexpression of PDGFR α and PDGFs, consistent with autocrine-mediated growth, has been found in subsets of glioblastomas, non-small cell lung cancers, and gastrointestinal stromal tumors.

**Target**

PDGFR α is a receptor tyrosine kinase that mediates signaling from PDGF ligands, and its activation has been implicated in cancer. Gene amplification and activating mutations of PDGFR α have been associated with increased metastatic potential in preclinical models. Coexpression of PDGFR α and PDGFs, consistent with autocrine-mediated growth, has been found in subsets of glioblastomas, non-small cell lung cancers, and gastrointestinal stromal tumors.
Active Trials Currently Not Enrolling

[NCT02451943] Sarcoma
ANNOUNCE: A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma

[NCT02659020] Sarcoma
ANNOUNCE 2: A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma

[NCT03126591] Sarcoma
A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma

Pipeline information is current through July 30, 2019.